- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Biocon Biologics has announced a board meeting to discuss the financial results for the quarter and half-year. Its biosimilar Yesintek™ (ustekinumab-kfce) now has broad U.S. market access, covering 100 million+ lives through major payers like Express Scripts, Cigna, and UnitedHealthcare. Positioned against Stelara®, Yesintek™’s strong payer adoption highlights Biocon’s solid commercial execution and supply chain strength, setting the stage for growth in the high-value biosimilars market.